iTeos Therapeutics (ITOS) Stock Forecast, Price Target & Predictions
ITOS Stock Forecast
iTeos Therapeutics stock forecast is as follows: an average price target of $38.50 (represents a 130.54% upside from ITOS’s last price of $16.70) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ITOS Price Target
The average price target for iTeos Therapeutics (ITOS) is $38.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $31.00. This represents a potential 130.54% upside from ITOS's last price of $16.70.
ITOS Analyst Ratings
According to 2 Wall Street analysts, iTeos Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ITOS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
iTeos Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 13, 2024 | Eva Fortea Verdejo | Wells Fargo | $31.00 | $14.50 | 113.79% | 85.63% |
| May 13, 2024 | Swayampakula Ramakanth | H.C. Wainwright | $46.00 | $17.44 | 163.76% | 175.45% |
The latest iTeos Therapeutics stock forecast, released on Aug 13, 2024 by Eva Fortea Verdejo from Wells Fargo, set a price target of $31.00, which represents a 113.79% increase from the stock price at the time of the forecast ($14.50), and a 85.63% increase from ITOS last price ($16.70).
iTeos Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $31.00 | $38.50 |
| Last Closing Price | $16.70 | $16.70 | $16.70 |
| Upside/Downside | -100.00% | 85.63% | 130.54% |
In the current month, the average price target of iTeos Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to iTeos Therapeutics's last price of $16.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 13, 2024 | Wells Fargo | - | Overweight | Initialise |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
iTeos Therapeutics's last stock rating was published by Wells Fargo on Aug 13, 2024. The company Initialise its ITOS rating from "null" to "Overweight".
iTeos Therapeutics Financial Forecast
iTeos Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.60M | $53.91M | $19.49M | - | $152.52M | $240.50M | $104.27M | - |
| Avg Forecast | $12.95M | $4.02M | $12.31M | $13.43M | $14.65M | $15.98M | $17.44M | $19.02M | $20.75M | $22.64M | $24.70M | $26.95M | $800.00K | $800.00K | $1.00M | - | $12.47M | $100.00M | $6.90M | $41.16M | $41.64M | $85.56M | $63.30M | $85.45M | $6.50M | $3.91M |
| High Forecast | $12.95M | $4.02M | $12.31M | $13.43M | $14.65M | $15.98M | $17.44M | $19.02M | $20.75M | $22.64M | $24.70M | $26.95M | $800.00K | $800.00K | $1.00M | - | $12.47M | $100.00M | $6.90M | $41.16M | $41.64M | $85.56M | $63.30M | $85.45M | $6.50M | $3.91M |
| Low Forecast | $12.95M | $4.02M | $12.31M | $13.43M | $14.65M | $15.98M | $17.44M | $19.02M | $20.75M | $22.64M | $24.70M | $26.95M | $800.00K | $800.00K | $1.00M | - | $12.47M | $100.00M | $6.90M | $41.16M | $41.64M | $85.56M | $63.30M | $85.45M | $6.50M | $3.91M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.83% | 1.31% | 0.47% | - | 2.41% | 2.81% | 16.04% | - |
iTeos Therapeutics's average Quarter revenue forecast for Oct 23 based on 1 analysts is $100.00M, with a low forecast of $100.00M, and a high forecast of $100.00M. ITOS's average Quarter revenue forecast represents a 693.97% increase compared to the company's last Quarter revenue of $12.60M (Mar 23).
iTeos Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-23.63M | $18.99M | $-14.30M | - | $121.74M | $-32.01M | $72.59M | $-26.31M |
| Avg Forecast | $5.77M | $1.79M | $5.49M | $5.99M | $6.53M | $7.12M | $7.77M | $8.48M | $9.25M | $10.09M | $11.01M | $12.01M | $356.61K | $356.61K | $445.76K | - | $5.56M | $44.58M | $3.08M | $18.35M | $18.56M | $38.14M | $28.22M | $38.09M | $2.90M | $-52.74M |
| High Forecast | $5.77M | $1.79M | $5.49M | $5.99M | $6.53M | $7.12M | $7.77M | $8.48M | $9.25M | $10.09M | $11.01M | $12.01M | $356.61K | $356.61K | $445.76K | - | $5.56M | $44.58M | $3.08M | $18.35M | $18.56M | $38.14M | $28.22M | $38.09M | $2.90M | $-42.19M |
| Low Forecast | $5.77M | $1.79M | $5.49M | $5.99M | $6.53M | $7.12M | $7.77M | $8.48M | $9.25M | $10.09M | $11.01M | $12.01M | $356.61K | $356.61K | $445.76K | - | $5.56M | $44.58M | $3.08M | $18.35M | $18.56M | $38.14M | $28.22M | $38.09M | $2.90M | $-63.29M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.68% | 1.03% | -0.77% | - | 4.31% | -0.84% | 25.05% | 0.50% |
1 analysts predict ITOS's average Quarter EBITDA for Mar 23 to be $3.08M, with a high of $3.08M and a low of $3.08M. This is -83.80% lower than iTeos Therapeutics's previous annual EBITDA (Dec 22) of $18.99M.
iTeos Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-15.55M | $20.45M | $991.00K | - | $69.58M | $-29.43M | $69.64M | $-26.46M |
| Avg Forecast | $-52.43M | $-61.60M | $-68.46M | $-79.13M | $-79.33M | $-78.53M | $-77.79M | $-85.36M | $-55.32M | $-58.81M | $-59.49M | $-55.37M | $-47.96M | $-46.47M | $-41.21M | $-35.22M | $-41.02M | $-41.72M | $-39.46M | $9.33M | $95.19M | $43.97M | $36.93M | $45.78M | $101.80M | $-52.92M |
| High Forecast | $-52.43M | $-61.60M | $-68.46M | $-79.13M | $-79.33M | $-78.53M | $-77.79M | $-85.36M | $-55.32M | $-58.81M | $-59.49M | $-55.37M | $-47.96M | $-40.17M | $-41.21M | $-35.22M | $-3.19M | $-21.70M | $-39.46M | $9.33M | $114.22M | $43.97M | $44.32M | $45.78M | $122.16M | $-42.33M |
| Low Forecast | $-52.43M | $-61.60M | $-68.46M | $-79.13M | $-79.33M | $-78.53M | $-77.79M | $-85.36M | $-55.32M | $-58.81M | $-59.49M | $-55.37M | $-47.96M | $-55.92M | $-41.21M | $-35.22M | $-72.88M | $-41.72M | $-39.46M | $9.33M | $76.15M | $43.97M | $29.55M | $45.78M | $81.44M | $-63.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.39% | 2.19% | 0.01% | - | 1.88% | -0.64% | 0.68% | 0.50% |
iTeos Therapeutics's average Quarter net income forecast for Mar 23 is $-39.46M, with a range of $-39.46M to $-39.46M. ITOS's average Quarter net income forecast represents a -292.94% decrease compared to the company's last Quarter net income of $20.45M (Dec 22).
iTeos Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.93M | $11.10M | $10.76M | - | $10.62M | $-30.87M | $8.76M | $15.10M |
| Avg Forecast | $16.28M | $5.05M | $15.47M | $16.87M | $18.41M | $20.08M | $21.91M | $23.90M | $26.08M | $28.45M | $31.04M | $33.87M | $1.01M | $1.01M | $1.26M | - | $15.67M | $125.66M | $8.67M | $51.72M | $11.97M | $107.51M | $5.63M | $107.38M | $8.17M | $4.91M |
| High Forecast | $16.28M | $5.05M | $15.47M | $16.87M | $18.41M | $20.08M | $21.91M | $23.90M | $26.08M | $28.45M | $31.04M | $33.87M | $1.01M | $1.01M | $1.26M | - | $15.67M | $125.66M | $8.67M | $51.72M | $14.37M | $107.51M | $6.76M | $107.38M | $8.17M | $4.91M |
| Low Forecast | $16.28M | $5.05M | $15.47M | $16.87M | $18.41M | $20.08M | $21.91M | $23.90M | $26.08M | $28.45M | $31.04M | $33.87M | $1.01M | $1.01M | $1.26M | - | $15.67M | $125.66M | $8.67M | $51.72M | $9.58M | $107.51M | $4.51M | $107.38M | $8.17M | $4.91M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.38% | 0.21% | 0.90% | - | 1.88% | -0.29% | 1.07% | 3.08% |
iTeos Therapeutics's average Quarter SG&A projection for Oct 23 is $125.66M, based on 1 Wall Street analysts, with a range of $125.66M to $125.66M. The forecast indicates a 953.57% rise compared to ITOS last annual SG&A of $11.93M (Mar 23).
iTeos Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Oct 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.03 | $0.03 | - | $1.96 | $-0.84 | $1.98 | $-0.75 |
| Avg Forecast | $-1.32 | $-1.55 | $-1.72 | $-1.99 | $-2.00 | $-1.98 | $-1.96 | $-2.15 | $-1.39 | $-1.48 | $-1.50 | $-1.39 | $-1.21 | $-1.17 | $-1.04 | $-0.98 | $-1.03 | $-1.16 | $-0.99 | $0.23 | $0.10 | $1.23 | $0.82 | $1.28 | $-0.53 | $-0.41 |
| High Forecast | $-1.32 | $-1.55 | $-1.72 | $-1.99 | $-2.00 | $-1.98 | $-1.96 | $-2.15 | $-1.39 | $-1.48 | $-1.50 | $-1.39 | $-1.21 | $-1.01 | $-1.04 | $-0.98 | $-0.08 | $-0.61 | $-0.99 | $0.23 | $0.10 | $1.23 | $0.82 | $1.28 | $-0.53 | $-0.41 |
| Low Forecast | $-1.32 | $-1.55 | $-1.72 | $-1.99 | $-2.00 | $-1.98 | $-1.96 | $-2.15 | $-1.39 | $-1.48 | $-1.50 | $-1.39 | $-1.21 | $-1.41 | $-1.04 | $-0.98 | $-1.84 | $-1.16 | $-0.99 | $0.23 | $0.10 | $1.23 | $0.82 | $1.28 | $-0.53 | $-0.41 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.44% | -0.11% | 0.29% | - | 2.39% | -0.66% | -3.76% | 1.81% |
According to 0 Wall Street analysts, iTeos Therapeutics's projected average Quarter EPS for Dec 22 is $0.23, with a low estimate of $0.23 and a high estimate of $0.23. This represents a 683.33% increase compared to ITOS previous annual EPS of $0.03 (Sep 22).
iTeos Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| SANA | Sana Bio | $4.47 | $12.00 | 168.46% | Buy |
| ERAS | Erasca | $2.97 | $7.00 | 135.69% | Buy |
| ITOS | iTeos Therapeutics | $16.70 | $38.50 | 130.54% | Buy |
| TCRX | TScan Therapeutics | $5.74 | $12.00 | 109.06% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| ANNX | Annexon | $7.20 | $14.00 | 94.44% | Buy |
| DSGN | Design Therapeutics | $5.54 | $9.67 | 74.55% | Buy |
| MLTX | MoonLake Immunotherapeutics | $51.14 | $79.33 | 55.12% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KYMR | Kymera Therapeutics | $46.08 | $51.10 | 10.89% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
ITOS Forecast FAQ
Is iTeos Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, iTeos Therapeutics (ITOS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ITOS's total ratings.
What is ITOS's price target?
iTeos Therapeutics (ITOS) average price target is $38.5 with a range of $31 to $46, implying a 130.54% from its last price of $16.7. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will iTeos Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ITOS stock, the company can go up by 130.54% (from the last price of $16.7 to the average price target of $38.5), up by 175.45% based on the highest stock price target, and up by 85.63% based on the lowest stock price target.
Can iTeos Therapeutics stock reach $30?
ITOS's average twelve months analyst stock price target of $38.5 supports the claim that iTeos Therapeutics can reach $30 in the near future.
What are iTeos Therapeutics's analysts' financial forecasts?
iTeos Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $67.09M (high $67.09M, low $67.09M), average EBITDA is $29.91M (high $29.91M, low $29.91M), average net income is $-321M (high $-321M, low $-321M), average SG&A $84.31M (high $84.31M, low $84.31M), and average EPS is $-8.086 (high $-8.086, low $-8.086). ITOS's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $42.7M (high $42.7M, low $42.7M), average EBITDA is $19.04M (high $19.04M, low $19.04M), average net income is $-262M (high $-262M, low $-262M), average SG&A $53.66M (high $53.66M, low $53.66M), and average EPS is $-6.59 (high $-6.59, low $-6.59).
Did the ITOS's actual financial results beat the analysts' financial forecasts?
Based on iTeos Therapeutics's last annual report (Dec 2023), the company's revenue was $12.6M, which missed the average analysts forecast of $119.37M by -89.45%. Apple's EBITDA was $-151M, missing the average prediction of $53.21M by -383.97%. The company's net income was $-113M, missing the average estimation of $-122M by -7.82%. Apple's SG&A was $50.4M, missing the average forecast of $150M by -66.40%. Lastly, the company's EPS was $-0.0031, missing the average prediction of $-3.191 by -99.90%. In terms of the last quarterly report (Mar 2023), iTeos Therapeutics's revenue was $12.6M, beating the average analysts' forecast of $6.9M by 82.54%. The company's EBITDA was $-23.63M, missing the average prediction of $3.08M by -868.27%. iTeos Therapeutics's net income was $-15.551M, missing the average estimation of $-39.462M by -60.59%. The company's SG&A was $11.93M, beating the average forecast of $8.67M by 37.56%. Lastly, the company's EPS was $-0.44, missing the average prediction of $-0.994 by -55.74%